News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Domestic business was up 41.9% YoY and 27.7% QoQ
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated
